Mesuximide
![]() | |
Clinical data | |
---|---|
Trade names | Celontin |
AHFS/Drugs.com | Consumer Drug Information |
MedlinePlus | a682028 |
Pregnancy category |
|
Routes of administration | By mouth (capsules) |
ATC code | N03AD03 (WHO) |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic (demethylation and glucuronidation) |
Metabolites | N-desmethylmethosuximide |
Biological half-life |
1.4–2.6 hours (mesuximide) 28–38 hours (active metabolite) |
Excretion | Urine |
Identifiers | |
| |
CAS Number |
77-41-8 ![]() |
PubChem (CID) | 6476 |
IUPHAR/BPS | 7228 |
DrugBank |
DB05246 ![]() |
ChemSpider |
6231 ![]() |
UNII |
0G76K8X6C0 ![]() |
KEGG |
D00404 ![]() |
ChEMBL |
CHEMBL697 ![]() |
ECHA InfoCard | 100.000.934 |
Chemical and physical data | |
Formula | C12H13NO2 |
Molar mass | 203.237 g/mol |
3D model (Jmol) | Interactive image |
Chirality | Racemic mixture |
| |
| |
![]() ![]() |
Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)[1] and Celontin (United States).[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.[3]
Medical use
is indicated for the control of absence seizures that are refractory to other drugs.[2]
References
- ↑ Pfizer AG (2005). "Petinutin (Mésuximide)". Official Pfizer AG Website (in French). Archived from the original on April 22, 2005. Retrieved August 21, 2006.
- 1 2 Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. Retrieved November 21, 2014.
- ↑ Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ. Plasma concentrations of phensuximide, methosuximide, and their metabolites in relation to clinical efficacy. Neurology 29: 1509-1513, 1979.
This article is issued from Wikipedia - version of the 9/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.